News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
180,432 Results
Type
Article (13239)
Company Profile (24)
Press Release (167168)
Multimedia
Podcasts (18)
Webinars (5)
Section
Business (48562)
Career Advice (614)
Deals (9090)
Drug Delivery (34)
Drug Development (28035)
Employer Resources (69)
FDA (4735)
Job Trends (3871)
News (91071)
Policy (7874)
Tag
2027 Pharm Country Standard (1)
Academia (1074)
Academic (1)
Accelerated approval (7)
Adcomms (9)
Allergies (53)
Alliances (13685)
ALS (60)
Alzheimer's disease (506)
Antibody-drug conjugate (ADC) (57)
Approvals (4866)
Artificial intelligence (116)
Autoimmune disease (31)
Automation (8)
Bankruptcy (70)
Best Places to Work (3194)
BIOSECURE Act (6)
Biosimilars (74)
Biotechnology (11)
Bladder cancer (45)
Brain cancer (16)
Breast cancer (186)
Cancer (1220)
Cardiovascular disease (151)
Career advice (528)
Career pathing (14)
CAR-T (76)
CDC (21)
Celiac Disease (1)
Cell therapy (183)
Cervical cancer (11)
Clinical research (24923)
Collaboration (366)
Company closure (1)
Compensation (41)
Complete response letters (9)
COVID-19 (1127)
CRISPR (21)
C-suite (189)
Cystic fibrosis (28)
Data (2032)
Denatured (9)
Depression (39)
Diabetes (183)
Diagnostics (1774)
Digital health (9)
Diversity (8)
Diversity, equity & inclusion (29)
Drug discovery (57)
Drug pricing (59)
Drug shortages (17)
Duchenne muscular dystrophy (71)
Earnings (14968)
Editorial (25)
Employer branding (5)
Employer resources (64)
Events (21747)
Executive appointments (245)
FDA (5595)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (380)
Gene editing (40)
Generative AI (12)
Gene therapy (163)
GLP-1 (356)
Government (1255)
Grass and pollen (3)
Guidances (107)
Healthcare (5378)
HIV (30)
Huntington's disease (12)
IgA nephropathy (21)
Immunology and inflammation (64)
Immuno-oncology (15)
Indications (26)
Infectious disease (1213)
Inflammatory bowel disease (66)
Inflation Reduction Act (6)
Influenza (35)
Intellectual property (28)
Interviews (105)
IPO (3440)
IRA (22)
Job creations (774)
Job search strategy (451)
JPM (16)
Kidney cancer (4)
Labor market (21)
Layoffs (104)
Leadership (17)
Legal (1534)
Liver cancer (27)
Longevity (3)
Lung cancer (129)
Lymphoma (108)
Machine learning (7)
Management (22)
Manufacturing (176)
MASH (67)
Medical device (3237)
Medtech (3254)
Mergers & acquisitions (5936)
Metabolic disorders (421)
Multiple sclerosis (75)
NASH (15)
Neurodegenerative disease (80)
Neuropsychiatric disorders (16)
Neuroscience (889)
NextGen: Class of 2026 (1995)
Non-profit (1641)
Now hiring (5)
Obesity (171)
Opinion (60)
Ovarian cancer (43)
Pain (52)
Pancreatic cancer (45)
Parkinson's disease (94)
Partnered (13)
Patents (41)
Patient recruitment (113)
Peanut (19)
People (17669)
Pharmaceutical (9)
Pharmacy benefit managers (11)
Phase 1 (5506)
Phase 2 (10728)
Phase 3 (10177)
Pipeline (1312)
Policy (104)
Postmarket research (1147)
Preclinical (2005)
Press Release (29)
Prostate cancer (82)
Psychedelics (16)
Radiopharmaceuticals (65)
Rare diseases (231)
Real estate (1389)
Recruiting (23)
Regulatory (6352)
Reports (14)
Research institute (910)
Resumes & cover letters (83)
Rett syndrome (2)
RNA editing (1)
RSV (28)
Schizophrenia (42)
Series A (78)
Series B (54)
Service/supplier (2)
Sickle cell disease (25)
Special edition (3)
Spinal muscular atrophy (67)
Sponsored (10)
Startups (1186)
Stomach cancer (5)
Supply chain (23)
Tariffs (17)
The Weekly (9)
Vaccines (382)
Venture capital (23)
Weight loss (126)
Women's health (22)
Worklife (8)
Date
Today (6)
Last 7 days (138)
Last 30 days (427)
Last 365 days (7091)
2026 (583)
2025 (7332)
2024 (8392)
2023 (9575)
2022 (12861)
2021 (14425)
2020 (14005)
2019 (13487)
2018 (10422)
2017 (9481)
2016 (9132)
2015 (10804)
2014 (7360)
2013 (5766)
2012 (6231)
2011 (6612)
2010 (5695)
Location
Africa (263)
Alabama (9)
Alaska (4)
Arizona (63)
Arkansas (2)
Asia (12960)
Australia (2478)
California (2229)
Canada (588)
China (354)
Colorado (74)
Connecticut (78)
Delaware (97)
Europe (34477)
Florida (345)
Georgia (111)
Idaho (15)
Illinois (241)
India (20)
Indiana (147)
Iowa (3)
Japan (176)
Kansas (39)
Kentucky (14)
Louisiana (10)
Maine (12)
Maryland (337)
Massachusetts (1504)
Michigan (52)
Minnesota (142)
Missouri (32)
Montana (6)
Nebraska (7)
Nevada (32)
New Hampshire (11)
New Jersey (773)
New Mexico (7)
New York (754)
North Carolina (287)
Northern California (1064)
Ohio (73)
Oklahoma (3)
Oregon (4)
Pennsylvania (478)
Puerto Rico (4)
Rhode Island (4)
South America (377)
South Carolina (10)
Southern California (897)
Tennessee (32)
Texas (293)
United States (8409)
Utah (56)
Virginia (50)
Washington D.C. (8)
Washington State (218)
Wisconsin (21)
Wyoming (2)
180,432 Results for "menarini group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
February 4, 2026
·
4 min read
Press Releases
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
November 24, 2025
·
8 min read
Press Releases
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
December 8, 2025
·
10 min read
Press Releases
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
December 23, 2025
·
4 min read
Press Releases
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
May 23, 2025
·
10 min read
Business
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries
Venatorx Pharmaceuticals and Menarini Group today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to commercialize, upon approval of relevant health authorities, cefepime-taniborbactam in 96 countries.
January 9, 2024
·
6 min read
Pharm Country
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
The Menarini Group, a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated results from phase 1b/2 ELECTRA and ELEVATE clinical studies evaluating elacestrant in combination with other treatments.
May 23, 2024
·
9 min read
Press Releases
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
March 20, 2025
·
8 min read
Press Releases
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
December 12, 2024
·
10 min read
Business
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU®
The Menarini Group and Stemline Therapeutics, Inc. presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments.
December 11, 2023
·
8 min read
1 of 18,044
Next
